Request Demo

Last update 20 Mar 2025

Thiamine Hydrochloride

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryThiamine Hydrochlorid (also known as Vitamin B1), is a small molecule drug that acts as a vitamin B1 supplement. Approved in December 1952, and is typically administered orally or intravenously.

Drug Type

Small molecule drug

Synonyms

Thiamine Chloride Hydrochloride, Thiamine chloride hydrochloride (JP17), Thiamine hydrochloride (USP)

+ [26]

Target-

Action-

Mechanism

Vitamin B1 supplements

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Thiamine Deficiency

Inactive Indication-

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Biological Therapies

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (01 Dec 1952),

Thiamine Deficiency

Regulation-

Structure/Sequence

Molecular FormulaC12H18Cl2N4OS

InChIKeyDPJRMOMPQZCRJU-UHFFFAOYSA-M

CAS Registry67-03-8

View All Structures (2)

200

Clinical Trials associated with Thiamine Hydrochloride

IRCT20190224042815N1

/ SuspendedPhase 2/3IIT

Evaluating the preventive effect of vitamin B1 on Delirium in critically ill patients

Start Date18 May 2640

Sponsor / Collaborator

Tehran University of Medical Sciences

ChiCTR2500096497

/ SuspendedEarly Phase 1IIT

Association between thiamine (vitamin B1) and riboflavin (vitamin B2) nutrition intervention on anxiety, stress and sleep quality

Start Date25 Jan 2025

Sponsor / Collaborator

Macau University of Science & Technology

NCT05083546

/ Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Thiamine Hydrochloride

100 Translational Medicine associated with Thiamine Hydrochloride

100 Patents (Medical) associated with Thiamine Hydrochloride

48,760

Literatures (Medical) associated with Thiamine Hydrochloride

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

Author: Dardouri, Mouna ; Nair, Kavita V. ; DiStefano, Michael J. ; Moore, Gina D. ; Saseen, Joseph J.

BackgroundHigh prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.MethodsWe conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.ResultsWe identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.ConclusionThis study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

01 Jun 2025·Comparative Biochemistry and Physiology Part D: Genomics and Proteomics

Multi-omics analysis reveals the cerebral sex-specific responses to chronic hypoxia in yellow catfish (Pelteobagrus fulvidraco)

Article

Author: Zhao, Cheng ; Yin, Danqing

Hypoxia disrupts multiple physiological processes, including metabolism, immunity, and reproduction in teleosts. The brain plays a critical role in adapting to environmental changes, regulating the endocrine system, and controlling reproduction. The present study investigated the sex-specific cerebral responses to chronic hypoxia through an integrated analysis of the transcriptome, proteome, and metabolome of yellow catfish. Common cerebral responses in both females and males included activation of the HIF signaling pathway, angiogenesis, and improved oxygen delivery by red blood cells. Reproductive defects were indicated by the downregulation of gh1, cga, and tshb in both sexes. Thyroid hormone homeostasis was more severely disrupted by hypoxia in females than in males, accompanied by a significant decrease in the level of VTG in the female brain. Damaged brain function was evidenced by the highly enriched pathways of "cytokine-cytokine receptor interaction" and "ECM-receptor interaction," and the blood-brain barrier (BBB) also appeared to be disrupted in female fish. In the male brain, reproductive-related genes or proteins, including prl, lepr, and AVP, were specifically decreased. Dysfunction in the male brain was also indicated by the enrichment of pathways such as "cytokine-cytokine receptor interaction" and "neuroactive ligand-receptor interaction," based on differentially expressed genes (DEGs) and proteins (DEPs). Additionally, chronic hypoxia appeared to inhibit cerebral amino acid metabolism in males. In summary, our results offer insight into understanding the sex-specific cerebral responses induced by chronic hypoxia in teleosts.

01 May 2025·Talanta

High-throughput and sustainable B vitamins analysis in nutritional supplements, vegetables, and fruits via 2D carbon microfiber fractionation system coupled with mass spectrometry

Article

Author: Yu, Yingli ; Qiu, Yu ; Nardiello, Donatella ; Shao, Miao ; Quinto, Maurizio ; Chen, Zhenyu ; Li, Donghao ; Yu, Chunyu ; Yang, Lei ; Cui, Meiyu

B vitamins are essential for energy metabolism, nervous health, blood production, and the immune system. Their quantification in nutritional supplements and food is mandatory to manage a correct daily intake and dosage. In this study, a fast and sustainable method for the analysis of 8 B vitamins (VB₁, VB₂, VB₃, nicotinamide, VB₅, VB₆, VB₉, VB₁₂) in real samples using a 2D-carbon microfiber fractionation system combined with a triple quadrupole mass spectrometer (2DμCFs-QqQ-MS/MS) is presented. The method shortens the analysis time to 5 min, showing high sensitivities (LODs: 1.7-13.7 ng mL^-1, LOQs: 5.5-45.7 ng mL^-1, obtained with standard solutions), good reproducibility (RSDs <15 %), and strong linear correlations (R² > 0.997). When applied for B vitamin determination in nutritional supplements, results matched product label values at a 95 % confidence level, with batch reproducibility never exceeding 5 %. Furthermore, coupling a 2D-carbon microfiber fraction system with a quadrupole time-of-flight high-resolution mass spectrometry (2DμCFs-QTOF-HRMS) it is possible to carry out quick monitoring of B vitamin contents together with impurity evaluation in real samples.

News (Medical) associated with Thiamine Hydrochloride

23 Sep 2024

·www.prnewswire.com

A PILL FOR ALZHEIMER'S DISEASE? CLINICAL TRIALS ON A NEW APPROACH TO TREATING ALZHEIMER'S STARTS AT 50 MEDICAL CENTERS ACROSS THE COUNTRY

NIH-funded trial will evaluate the effects of a synthetic version of vitamin B1 on cognitive function that was developed by Burke Institute for people with early Alzheimer's disease For more information about the trial and to find a study site, visit benfoteam.org WHITE PLAINS, N.Y., Sept. 23, 2024 /PRNewswire/ -- A completely different approach to stopping the progression of Alzheimer's disease pioneered by a research institute based in Westchester County, NY is now being tested nationwide. The Burke Neurological Institute (BNI), an affiliation of Weill Cornell Medicine, in partnership with the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego and Columbia University Irving Medical Center, have launched a national clinical trial to investigate the therapeutic potential of a BNI and Weill Cornell Medicine-developed form of benfotiamine, a synthetic version of vitamin B1 (thiamine), as a treatment for mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The BenfoTeam trial (The Phase 2A-2B study) taking place at 50 sites across the U.S. will evaluate the effects of benfotiamine on cognitive function and whether high doses benefit people 50-89 with mild AD and MCI. The trial is funded by the National Institute on Aging (NIA), a part of the National Institutes of Health (NIH). Benfotiamine is a synthetic drug which can increase blood thiamine up to 100 times the normal level. These levels of blood thiamine cannot be achieved by taking thiamine alone. The brain tissue in people with AD shows a thiamine deficiency, even with a sufficient supply of thiamine in a person's blood. The trial is investigating whether the delivery of thiamine via drug will increase the amount of thiamine getting to the brain and slow cognitive decline in people with early AD. Currently, 5.8 million Americans are living with AD with this number projected to rise to nearly 14 million people by 2050. "The approach of using benfotiamine in patients with mild Alzheimer's is very promising," said Rajiv Ratan, M.D., Ph.D., Executive Director at Burke Neurological Institute. "This clinical trial builds on years of hard work to address a disease that affects millions of patients " Howard Feldman, Director of the ADCS at UC San Diego said, "The launch of the BenfoTeam clinical trial represents a fresh approach with a potential treatment that is readily accessible, scientifically compelling, and cost-effective – that's a trifecta for a potential AD therapy in a Phase 2 trial – and benfotiamine has a strong safety profile." Gary E. Gibson, Ph.D., Professor of Neurosciences at BNI, has spent decades conducting studies to better understand Alzheimer's disease and how to develop new therapies to treat the disease. The BenfoTeam study builds on Gibson's scientific research conducted at Burke Neurological Institute – the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord. Gibson said many existing treatments or drugs in development only treat the symptoms of Alzheimer's disease such as amyloid plaques, but do not address the root cause of the disease. Benfotiamine has been shown to improve memory and diminish plaques, tangles, inflammation, and oxidative stress in animal models. In addition, unlike many of the other recently approved treatments for Alzheimer's disease, benfotiamine can be taken by mouth and does not require infusions. "In people with Alzheimer's disease, reductions in brain glucose utilization track closely with cognitive decline and we already know that thiamine deficiencies can cause dementia," said Gibson, who is also a Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine. "We think people with mild cognitive impairment and Alzheimer's disease may not be getting enough thiamine delivered to the brain." Jose Luchsinger, M.D., MPH, Vice-Chair for Clinical and Epidemiologic Research at Columbia University and a BenfoTeam trial co-Principal Investigator said, "While Alzheimer's disease impacts all aging populations, it is not clear that recently approved Alzheimer's therapies benefit underrepresented racial and ethnic groups. The BenfoTeam trial is designed for all patient populations.'' Participation in the trial for each patient will last 18 months (plus screening) and enrollment is planned for 406 participants. For more information about the trial and to find a study site, visit benfoteam.org or call 877-807-1290 (toll free). This research will be supported by the NIH's National Institute on Aging (R01AG076634). This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH's National Institute on Aging. The ClinicalTrials.gov ID number for this study is: NCT06223360. About the BenfoTeam Partnership The BenfoTeam clinical research trial is funded by a grant from the National Institute on Aging (NIA) (R01AG076634). The clinical research trial is coordinated by the Alzheimer's Disease Cooperative Study (ADCS) at University of California San Diego School of Medicine and is led by principal investigators from the Burke Neurological Institute and Weill Cornell Medicine, Columbia University Irving Medical Center, and UC San Diego. SOURCE Burke Neurological Institute WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

03 Sep 2024

·www.drugs.com

Global Study Reveals Widespread Micronutrient Deficiencies

TUESDAY, Sept. 3, 2024 -- More than 5 billion people globally do not consume enough iodine, vitamin E, and calcium, according to a study published online Aug. 29 in The Lancet Global Health . Simone Passarelli, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues estimated micronutrient intake using a novel approach accounting for the shape of a population's nutrient intake distribution, based on dietary intake data from 31 countries. These distributions were applied to data for 185 countries for 34 age-sex groups to estimate the prevalence of nutrient intakes for 99.3 percent of the global population. The researchers found that more than 5 billion people do not consume enough iodine, vitamin E, and calcium (68, 67, and 66 percent of the global population, respectively). More than 4 billion people do not consume enough iron, riboflavin, folate, and vitamin C (65, 55, 54, and 53 percent, respectively). Within the same country and age groups, estimated inadequate intakes were higher for women with regards to iodine, vitamin B 12 , iron, and selenium, and for men with regards to magnesium, vitamin B 6 , zinc, vitamin C, vitamin A, thiamin, and niacin. "We hope this analysis sheds light on crucial nutrition challenges for locations without the necessary means to collect primary data, and improves understanding of global micronutrient inadequacy so that public health interventions can more effectively address deficiencies," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

30 Aug 2024

·www.drugs.com

Billions of the World's People Deficient in Essential Micronutrients

FRIDAY, Aug. 30, 2024 -- More than half of people around the world aren’t getting enough micronutrients essential to human health, including calcium, iron and vitamins C and E, a new study says. These deficiencies are contributing to global malnutrition, as well as health problems like blindness, increased vulnerability to infections, and pregnancy complications, researchers said in The Lancet Global Health . “These results are alarming,” researcher Ty Beal , a senior technical specialist at the Global Alliance for Improved Nutrition, said in a news release. “Most people — even more than previously thought, across all regions and countries of all incomes — are not consuming enough of multiple essential micronutrients,” Beal said. “These gaps compromise health outcomes and limit human potential on a global scale.” For the study, researchers combined data from several sources to compare the nutritional intake of people in 185 countries. The team specifically assessed intake of 15 vitamins and minerals -- calcium, iodine, iron, riboflavin, folate, zinc, magnesium, selenium, thiamin, niacin, and vitamins A, B6 , B12, C and E. Researchers found widespread inadequate intake of iodine (68% of the world's population); vitamin E (67%); calcium (66%); and iron (65%). More than half of people consume inadequate levels of riboflavin, folate, and vitamins C and B6, researchers added. Intake of niacin was closest to sufficient, with 22% of people worldwide consuming too little, followed by thiamin (30%) and selenium (37%). “The public health challenge facing us is immense, but practitioners and policymakers have the opportunity to identify the most effective dietary interventions and target them to the populations most in need,” senior author Christopher Golden , associate professor of nutrition and planetary health at the Harvard T.H. Chan School of Public Health, said in a news release. Women were more likely than men to get too little iodine, vitamin B12, iron and selenium, results indicate. On the other hand, men weren't getting enough niacin, thiamin, zinc, magnesium, and vitamins A, C, and B6 compared to women, researchers said. Children and young adults 10 to 30 were most prone to low calcium intake, especially in South and East Asia and sub-Saharan Africa. Calcium intake was also low across North America, Europe and Central Asia. “Our study is a big step forward,” co-lead author Chris Free , a research professor at the University of California-Santa Barbara, said in a news release. “Not only because it is the first to estimate inadequate micronutrient intakes for 34 age-sex groups in nearly every country, but also because it makes these methods and results easily accessible to researchers and practitioners.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Thiamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02094	Thiamine Hydrochloride	A11DA01	DB00152

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thiamine Deficiency	United States	-	-
Thiamine Deficiency	Canada	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03746106 (CTgov)	Phase 4	Thiamine Deficiency	7	Thiamine (Thiamine Alone)	ewfizgsmhv(ypilcjokpn) = cfpnaitinj cbufindnnx (rdqwfzlwxz, syqypmrcyy - uciexpdglo) View more	-	03 Jan 2025
				Thiamine+Trimethoprim (Thiamine Co-administered With Trimethoprim)	ewfizgsmhv(ypilcjokpn) = ovpqoekfwi cbufindnnx (rdqwfzlwxz, sfosczhrxf - rtqqtgksoe) View more
NCT03550794 \| NCT01070810 (Pubmed) Manual	Phase 2	Shock, Septic	158	Thiamine administration	-	Positive	06 Feb 2024
IRCT201510266917N3 (not available, Pubmed \| Int J Fertil Steril)	Phase 1	Polycystic Ovary Syndrome	64	Vitamin B1	ffinmtyhgo(qsgmnmlapm) = jleeyiwdis wemqzghhov (wqudpolyey ) View more	Positive	02 Feb 2024
				Thiamine (Placebo)	ffinmtyhgo(qsgmnmlapm) = jtxjxdbrir wemqzghhov (wqudpolyey )
NCT03450707 (THACA, CTgov)	Phase 2	Heart Arrest	93	Thiamine 500 mg IV (Thiamine)	holxihbrqs(jxcrfkoiap) = dggqelfyhk zezukcsczb (lvjrjyisyq, qqezuuihqq - qpcaosbkqx) View more	-	24 Aug 2023
				Placebo (Placebo)	holxihbrqs(jxcrfkoiap) = fmjyqxdguw zezukcsczb (lvjrjyisyq, jehmsnmurp - nuecndpvry) View more
NCT03550794 (TRPSS, CTgov)	Phase 2	Kidney Diseases \| Thiamine Deficiency \| Shock, Septic	95	Thiamine Hydrochloride (Thiamine)	iqlzhvbjki(lhgxszkvhp) = czajwhecqr irgvkvjnfx (xkbtkweqdm, xhsqapltly - ewejmxadkt) View more	-	27 Jun 2023
				Placebo (Placebo)	iqlzhvbjki(lhgxszkvhp) = afumcsacup irgvkvjnfx (xkbtkweqdm, okdtuexxeg - zdfuwwsnxj) View more
NCT03550794 (TRPSS, Pubmed \| Am J Respir Crit Care Med)	Phase 2	Shock, Septic	95	Thiamine	cbzovqaiei(otfcrnirds) = pixtftklwj deijfhwuyz (pfuqocndie ) View more	-	26 Jun 2023
				Placebo	cbzovqaiei(otfcrnirds) = xkeycpfpbu deijfhwuyz (pfuqocndie ) View more
EHA2023	Not Applicable	Vitamin B12 Deficiency Anaemia	37	Daily oral vitamin B12	auekqkfjlx(qjkqxjwnhy) = jvhixpyjkk rxwtfninnc (dnwbutieii )	-	08 Jun 2023
				Weekly intravenous vitamin B12	auekqkfjlx(qjkqxjwnhy) = khngiznzrf rxwtfninnc (dnwbutieii )
AAIC2021	Not Applicable	Cognitive Dysfunction \| Dementia	46,175	B vitamins	ezmwfrrhwy(zeebveggqi): OR = 1.76 (95% CI, 1.24 - 2.5)	-	31 Dec 2021
				B vitamins (Placebo)
NCT03422159 (ORANGES, CTgov)	Phase 2	Shock, Septic	140	thiamine+Ascorbic Acid+Hydrocortisone (Treatment Arm)	lrlzvazzea(trcuqmjonn) = bxbtcrsazt egbwodaizi (tjelfuyrxv, ujuulcpkvh - ftcummdyal) View more	-	21 Sep 2021
				Sodium Chloride 0.9% (Placebo Arm)	lrlzvazzea(trcuqmjonn) = ezauwpsjbh egbwodaizi (tjelfuyrxv, xjhnvwfmza - ogmpkkezxu) View more
Pubmed \| Int J Crit Illn Inj Sci	Not Applicable	Shock, Septic	-	Thiamine	(xpjwpwqyhv): RR = 0.96 (95% CI, 0.72 - 1.28), P-Value = 0.774	-	01 Apr 2021
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis